Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of co-administration of alendronate and allan sodium phosphate for the management of osteoporosis

Jialian Chen, Xiong Peng , Fei Hu

Second Department of Orthopedics, Hanchuan City People's Hospital, Hanchuan City, China;

For correspondence:- Xiong Peng Email: id1170@163.com

Accepted: 22 December 2018 Published: 31 January 2019

Citation: Chen J, Peng X, Hu F. Effect of co-administration of alendronate and allan sodium phosphate for the management of osteoporosis. Trop J Pharm Res 2019; 18(1):49-54 doi: 10.4314/tjpr.v18i1.8

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the therapeutic effect of combination of alendronate and allan sodium phosphate on osteoporosis.

Methods: Patients diagnosed with osteoporosis (100) were randomly assigned to control and study groups (50 subjects/group). The control group received conventional calcium treatment (calcium carbonate D3) after surgery. They consisted of 21 males and 29 females aged 62 to 78 years. The observation group consisted of 22 males and 28 females aged 63 to 77 years (mean age = 68.90 ± 6.43 years), and were treated with sodium alendronate and allan sodium phosphate. Bone mineral density (BMD), bone pain score, clinical effectiveness and levels of calcium, phosphorus, osteocalcin, collagen N-terminal peptide (NTX) and urinary calcium/creatinine were determined using ELISA kits.

Results: After 1 year of treatment, lumbar vertebral and femoral neck BMD significantly increased in both groups. The study group had significantly higher BMD than the controls (p < 0.05). Blood calcium levels increased significantly after 1 year in both groups. The treatment led to a higher level of osteocalcin in the study group than in the control group (p < 0.05). However, the treatment brought about significantly lower NTX level in the study group than in controls.

Conclusion: The results indicate that combined administration of sodium alendronate and allan sodium phosphate is effective for the treatment of osteoporosis.

Keywords: Osteoporosis, Allan sodium phosphate, Alendronate, Apoptosis-related factors, Calcium